AlphAIalphai — Financial news for AI agents
MarketBeatMAY 212 min read$TCMD

BTIG Research Reiterates Buy Rating for Tactile Systems Technology (NASDAQ:TCMD)

BTIG Research has reiterated a "Buy" rating for Tactile Systems Technology (NASDAQ:TCMD) and maintained a $40 price target, suggesting a potential 61% upside. Other analysts also have a "Moderate Buy" consensus with an average target of $38.60. The company recently reported mixed quarterly results, missing EPS estimates but exceeding revenue expectations, with shares trading around $24.84.

Original reporting
MarketBeat · MarketBeat
Published May 21, 2026, 12:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 21, 2026, 1:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
BTIG Research Reiterates Buy Rating for Tactile Systems Technology (NASDAQ:TCMD) — source image
Source · MarketBeat
Decision brief

The 30-second read

$TCMDBullishMed
01

Why it matters

The reaffirmed buy rating and high price target may lead to increased investor interest and upward price movement, but caution is warranted due to recent earnings miss.

02

Market read

The news is highly relevant for investors interested in healthcare and medical device sectors, with potential short- to medium-term trading opportunities.

03

What to watch

Potential risks include market volatility, regulatory changes, or slower-than-expected revenue growth, which could temper the optimistic outlook.

Timing: Immediate to short-term (next 1-3 months)

Background

Tactile Systems Technology specializes in medical devices for the treatment of chronic conditions, with recent quarterly results showing mixed performance.

Company-level read

Ticker impact

$TCMDBullishHigh confidence
Context

The news pertains directly to Tactile Systems Technology, with a high relevance score of 1.0, indicating significant impact potential.

Expected impact

Potential upward movement towards $40 over the next 6-12 months, contingent on continued positive analyst sentiment and company performance.

Evidence & confidence

The reaffirmed buy rating, high target price, and analyst consensus indicate strong institutional support and positive market sentiment, increasing the likelihood of stock appreciation.

Market effects

Sector

Positive outlook for the medical device sector, particularly companies specializing in life sciences and healthcare technology.

Regional

Potential uplift in regional markets where Tactile Systems Technology operates, especially in North America.

Global

Moderate; reflects sector-wide optimism but limited global macroeconomic influence.

Counterpoint

What could challenge this read

Some analysts may view the recent mixed quarterly results as a warning sign, suggesting caution before committing to a bullish position.

Key entities

  • Company
    Tactile Systems Technology

    A medical device company focused on therapies for chronic conditions.

Read at source← All news

Related articles

AUG 10
$TCMDHigh

TACTILE SYSTEMS TECHNOLOGY INC (TCMD): Results of Operations and Financial Condition

TACTILE SYSTEMS TECHNOLOGY INC (TCMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tcmd-20260810xex99d1.htm EX-99.1 Exhibit 99.1 Tactile Systems Technology, Inc. Reports Second Quarter 2026 Financial Results MINNEAPOLIS, MN, August 10th, 2026 – Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology com

SEC EDGAR 8-K6 min
JUN 2
$TCMDMedAI 8/10

Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy

Tactile Medical (Nasdaq: TCMD) announced the full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation system. The company says it keeps the same use for chronic neuromuscular and respiratory conditions such as cystic fibrosis and bronchiectasis across ages, while adding a lighter, more adjustable vest and a redesigned controller. It also includes built-in Wi‑Fi/Bluetooth for connected care and clinician/payer data.

manilatimes.net4 min
AUG 11
$DISMed

Disney, Comcast reach deal, lifting NFL Network blackout

Comcast and Disney reached an agreement to end the NFL Network blackout for Comcast Xfinity TV subscribers, resuming NFL Network and NFL RedZone in time for the 2026 season. The blackout began after their contract expired in late April. Disney owns 72% of ESPN, which took over NFL Media assets earlier this year. Terms were not disclosed.

740thefan.com3 min
AUG 11
$ABUSMed

Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?

Arbutus Biopharma (ABUS) received about $178 million from Moderna (MRNA) as its share of a $950 million noncontingent LNP patent settlement, with reimbursement of legal costs and an expected Q3 dividend tied to Genevant. ABUS reported Q1 2026 revenue of $179.1 million and net income of $169.7 million. Moderna reported Q2 2026 revenue of $145 million and a net loss of $782 million, plus FDA approval for mFLUSIVA.

insidermonkey.com6 min
AUG 11
$IONQMedAI 8/10

Pentagon may see one of quantum computing’s first practical winners

IonQ (IONQ) said DARPA awarded a $28 million contract modification under its It’s About Time program to support production development and 25 Evergreen-05 optical atomic clocks, with a $30 million option for 100 additional clocks. IonQ plans to invest $15 million to scale manufacturing. The company cites timing performance for GPS-denied defense uses.

yahoo.com6 min
AUG 11
$CCEYFMedAI 8/10

CanCambria Energy Provides Updated Contingent Resource Evaluation for Flagship Deep Gas Project, Attributable to Strong European Natural Gas Prices, Driving an Increased NPV10 of US$2.04 Billion

CanCambria Energy Corp. (TSXV: CCEC) reported an updated independent contingent resource evaluation for its 100% owned Kiskunhalas deep gas project in southern Hungary. Prepared by CHPE (effective June 30, 2026), it assumes $12.00/MMBtu TTF1 gas. Risked 2C Development Pending NPV10 rose 16% to US$2.04B from US$1.762B; 2C volumes are 571.9 Bcf and 59.6 MMbbl. First gas is targeted for mid-2027.

oilandgas360.com4 min